ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.
ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.
Kosiborod, a cardiologist, and Skolnik, a family practitioner, agree no single specialty owns that prescription and that "it takes a village to care for a patient."
Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.
Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.
High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.
PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.
The cardiac myosin inhibitor is the only treatment that targets the pathophysiology of the disease, improving patient function and symptoms.
Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.
In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.